Search

Your search keyword '"Amino, Yoshiaki"' showing total 38 results

Search Constraints

Start Over You searched for: Author "Amino, Yoshiaki" Remove constraint Author: "Amino, Yoshiaki"
38 results on '"Amino, Yoshiaki"'

Search Results

5. Serum CYFRA 21-1 as a Prognostic Marker in Non-Small-Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors.

8. Efficacy of osimertinib in patients with EGFR‐mutation positive non‐small cell lung cancer with malignant pleural effusion

10. Clinical characteristics of patients with KRAS mutation detected by liquid biopsy

11. Dissociated responses at initial computed tomography evaluation is a good prognostic factor in non-small cell lung cancer patients treated with anti-programmed cell death-1/ligand 1 inhibitors

12. Real-world outcome analysis of patients with stage IV non-small cell lung cancer treated with tyrosine kinase and immune checkpoint inhibitors

14. Advances in the treatment of postoperative recurrence of non–small cell lung cancer and their impact on survival in Asian patients

15. MO45-3 The efficacy of osimertinib in patients with EGFR-positive non-small cell lung cancer with malignant pleural effusion

16. Rapid genomic profiling of circulating tumor DNA in non-small cell lung cancer using Oncomine Precision Assay with GenexusTM integrated sequencer

17. Minimal Change Disease Associated With Durvalumab

18. Characteristics of central nervous system progression in non‐small cell lung cancer treated with crizotinib or alectinib

19. Impact of Renin–angiotensin System Inhibitors on the Efficacy of Anti-PD-1/PD-L1 Antibodies in NSCLC Patients

20. Clinical influence of switching companion diagnostic tests for EGFR‐TKs from Therascreen to Cobas v2

21. Feasibility of next‐generation sequencing test for patients with advanced NSCLC in clinical practice

22. Poor efficacy of anti‐programmed cell death‐1/ligand 1 monotherapy for non‐small cell lung cancer patients with active brain metastases

23. Addition of ramucirumab enhances docetaxel efficacy in patients who had received anti-PD-1/PD-L1 treatment

24. Efficacy of anti-programmed cell death-1/ligand 1 monotherapy for non-small cell lung cancer patients with active brain metastases.

25. Dissociated responses at initial computed tomography evaluation is a good prognostic factor in non-small cell lung cancer patients treated with anti-program cell death-1/ligand 1 inhibitors

26. Association Between the Efficacy of Pembrolizumab and Low STK11/LKB1 Expression in High-PD-L1-expressing Non-small-cell Lung Cancer

27. Dissociated responses at initial computed tomography evaluation is a good prognostic factor in non-small cell lung cancer patients treated with anti-program cell death-1/ligand 1 inhibitors

28. Association of High Neutrophil-to-Lymphocyte Ratio With Poor Outcomes of Pembrolizumab Therapy in High-PD-L1-expressing Non-small Cell Lung Cancer

30. Feasibility of next‐generation sequencing test for patients with advanced NSCLC in clinical practice.

32. A retrospective analysis of the efficacy of immune checkpoint inhibitors (ICIs) to advanced non-small cell cancer (NSCLC) patients (pts) with central nerve system (CNS) metastasis.

Catalog

Books, media, physical & digital resources